STEMart announces the expansion of its genetic toxicology capabilities with the In Vivo Rat Micronucleus Test services.

Waters has announced the completion of its acquisition of BD’s Biosciences and Diagnostic Solutions businesses.

The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

FAYETTEVILLE, GA, UNITED STATES, February 7, 2026 /EINPresswire.com/ -- Accurately isolating individual cells from ...

Q4 2025 Earnings Call February 9, 2026 8:30 AM ESTCompany ParticipantsCaspar Tudor - Head of Investor RelationsUdit Batra ...

Turning to the acquired business contribution, following today's expected close of the transaction, we expect the Biosciences ...

A new study may change the way scientists think about the distance traveled by tiny bubbles carrying signals between cells ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

Artificial intelligence (AI) is now an essential tool in biopharma manufacturing, yet industry still needs guidelines on how LLMs, ML, and other technologies should be used in drug making, say the ...

An fresh look at trial results that propelled the only FDA approval of a chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) shows prior treatment with ibrutinib, a ...